MetaCap

Decoy Therapeutics (DCOY) vs XORTX Therapeutics (XRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Decoy Therapeutics is the larger company by market cap ($2.0 million vs $1.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DCOY-48.48%XRTX-51.92%
+9%-23%-55%
Oct 7, 20261 yearNov 20, 2026
DCOY-43.58%XRTX-40.50%
+2%-22%-46%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DCOY versus XRTX key metrics
MetricDCOYXRTX
Share price$0.8294$0.839
Market cap$1.98M$1.88M
1-day change-4.68%-5.73%
P/E ratio (TTM)0.03—
Forward P/E—1.05
EPS (TTM)$31.19$-2.09
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-12.52M—
52-week high$16.92$3.60
52-week low$0.80$0.81
Distance from 52-week high-95.10%-76.69%
Analyst consensusstrong_buy—
Avg. price target upside+261.71%—
Average volume2.17M776.48K
Shares outstanding2.39M2.25M
Employees11—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Decoy Therapeutics

DCOY stock →

Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company.

Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees

About XORTX Therapeutics

XRTX stock →

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.

Health Care · Biotechnology: Pharmaceutical Preparations

DCOY vs XRTX FAQ

Which is bigger, Decoy Therapeutics or XORTX Therapeutics?

Decoy Therapeutics (DCOY) is larger, with a market capitalization of $1.98M compared with $1.88M for XORTX Therapeutics (XRTX).

Are Decoy Therapeutics and XORTX Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons